$410m Ambit deal bolsters Daiichi Sankyo's oncology presence

Daiichi Sankyo is to purchase US oncology-focused venture Ambit Biosciences for up to $410m, bringing the major Japanese firm an attractive Phase III asset for acute myeloid leukemia and boosting its oncology pipeline.